JPH11507845A - 神経細胞付着分子スプライシング変種 - Google Patents

神経細胞付着分子スプライシング変種

Info

Publication number: JPH11507845A
Authority: JP; Japan
Prior art keywords: polypeptide; nrcamvar; polynucleotide; seq; sequence
Prior art date: 1997-02-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP10535471A

Other languages

English (en)

Japanese (ja)

Inventor

テレット，ジョナサン・アレキサンダー

ケンリック，スーザン・ジェーン

ワン，ボ

Original Assignee

スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-13

Filing date

1998-02-12

Publication date

1999-07-13

1997-02-13 Priority claimed from GBGB9703011.8A external-priority patent/GB9703011D0/en

1998-02-12 Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

1999-07-13 Publication of JPH11507845A publication Critical patent/JPH11507845A/ja

Status Pending legal-status Critical Current

Links

102000001068 Neural Cell Adhesion Molecules Human genes 0.000 title 1
108010069196 Neural Cell Adhesion Molecules Proteins 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 193
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 188
229920001184 polypeptide Polymers 0.000 claims abstract description 185
108091033319 polynucleotide Proteins 0.000 claims abstract description 76
102000040430 polynucleotide Human genes 0.000 claims abstract description 76
239000002157 polynucleotide Substances 0.000 claims abstract description 75
238000000034 method Methods 0.000 claims abstract description 72
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 13
206010028980 Neoplasm Diseases 0.000 claims abstract description 12
208000008589 Obesity Diseases 0.000 claims abstract description 12
201000011510 cancer Diseases 0.000 claims abstract description 12
235000020824 obesity Nutrition 0.000 claims abstract description 12
238000011282 treatment Methods 0.000 claims abstract description 11
210000004027 cell Anatomy 0.000 claims description 65
125000003729 nucleotide group Chemical group 0.000 claims description 43
239000002773 nucleotide Substances 0.000 claims description 41
108090000623 proteins and genes Proteins 0.000 claims description 36
230000000694 effects Effects 0.000 claims description 30
108020004414 DNA Proteins 0.000 claims description 28
239000012634 fragment Substances 0.000 claims description 27
230000014509 gene expression Effects 0.000 claims description 27
150000001875 compounds Chemical class 0.000 claims description 24
125000003275 alpha amino acid group Chemical group 0.000 claims description 21
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
239000000523 sample Substances 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
239000000556 agonist Substances 0.000 claims description 12
108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
239000005557 antagonist Substances 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
238000009396 hybridization Methods 0.000 claims description 10
230000027455 binding Effects 0.000 claims description 9
239000003446 ligand Substances 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 7
230000035772 mutation Effects 0.000 claims description 7
239000000758 substrate Substances 0.000 claims description 6
210000000170 cell membrane Anatomy 0.000 claims description 5
230000005764 inhibitory process Effects 0.000 claims description 5
230000004044 response Effects 0.000 claims description 5
230000000295 complement effect Effects 0.000 claims description 3
230000000638 stimulation Effects 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
230000001131 transforming effect Effects 0.000 claims description 2
230000000735 allogeneic effect Effects 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
238000003556 assay Methods 0.000 abstract description 12
238000010188 recombinant method Methods 0.000 abstract description 2
241000282414 Homo sapiens Species 0.000 description 33
239000002299 complementary DNA Substances 0.000 description 26
101150031836 NRCAM gene Proteins 0.000 description 20
239000000203 mixture Substances 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 15
241000287828 Gallus gallus Species 0.000 description 14
235000013330 chicken meat Nutrition 0.000 description 14
235000018102 proteins Nutrition 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 13
238000009472 formulation Methods 0.000 description 11
210000004556 brain Anatomy 0.000 description 10
239000013598 vector Substances 0.000 description 10
241000124008 Mammalia Species 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
210000000349 chromosome Anatomy 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
238000012216 screening Methods 0.000 description 6
230000004913 activation Effects 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
229960005486 vaccine Drugs 0.000 description 5
102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
238000007792 addition Methods 0.000 description 4
230000003321 amplification Effects 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000002759 chromosomal effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000007423 screening assay Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
241000700605 Viruses Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
230000004481 post-translational protein modification Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000008569 process Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
230000005730 ADP ribosylation Effects 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
210000004404 adrenal cortex Anatomy 0.000 description 2
230000001919 adrenal effect Effects 0.000 description 2
210000001943 adrenal medulla Anatomy 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000006664 bond formation reaction Methods 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000006251 gamma-carboxylation Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000007614 genetic variation Effects 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000033444 hydroxylation Effects 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102000008102 Ankyrins Human genes 0.000 description 1
108010049777 Ankyrins Proteins 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000212384 Bifora Species 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102000006630 Contactin 2 Human genes 0.000 description 1
108010087196 Contactin 2 Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000001308 Fasciculation Diseases 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
101001023792 Gallus gallus Neurofascin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010028293 Muscle contractions involuntary Diseases 0.000 description 1
101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
101100240988 Rattus norvegicus Nrcam gene Proteins 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000014107 chromosome localization Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
229960004675 fusidic acid Drugs 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
210000000020 growth cone Anatomy 0.000 description 1
150000003278 haem Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
230000004203 pancreatic function Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000015927 pasta Nutrition 0.000 description 1
230000007170 pathology Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
210000004281 subthalamic nucleus Anatomy 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000008189 vertebrate development Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

JP10535471A 1997-02-13 1998-02-12 神経細胞付着分子スプライシング変種 Pending JPH11507845A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9703011.8A GB9703011D0 (en)	1997-02-13	1997-02-13	Novel compounds
EP97305485		1997-07-22
EP9703011.8		1997-07-22
EP97305485.1		1997-07-22
PCT/GB1998/000434 WO1998036062A1 (fr)	1997-02-13	1998-02-12	Variantes d'epissage de molecule d'adherence cellulaire neuronale

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002002285A Division JP2002300892A (ja)	1997-02-13	2002-01-09	神経細胞付着スプライシング変種

Publications (1)

Publication Number	Publication Date
JPH11507845A true JPH11507845A (ja)	1999-07-13

Family

ID=26147528

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP10535471A Pending JPH11507845A (ja)	1997-02-13	1998-02-12	神経細胞付着分子スプライシング変種
JP2002002285A Pending JP2002300892A (ja)	1997-02-13	2002-01-09	神経細胞付着スプライシング変種

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2002002285A Pending JP2002300892A (ja)	1997-02-13	2002-01-09	神経細胞付着スプライシング変種

Country Status (4)

Country	Link
EP (1)	EP0910641A1 (fr)
JP (2)	JPH11507845A (fr)
CA (1)	CA2243984A1 (fr)
WO (1)	WO1998036062A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017000148A (ja) *	2008-10-01	2017-01-05	イマティクスバイオテクノロジーズゲーエムベーハー	神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7034132B2 (en)	2001-06-04	2006-04-25	Anderson David W	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1259819A2 (fr) *	2000-02-24	2002-11-27	Oxford GlycoSciences (UK) Limited	Diagnostic de maladies affectives bipolaires (bad) et de depressions unipolaires
AU2001249835A1 (en) *	2000-04-03	2001-10-15	Oxford Glycosciences (Uk) Ltd.	Diagnosis and treatment of alzheimer's disease
US6852874B2 (en) *	2000-10-02	2005-02-08	The Scripps Research Institute	Second cycle asymmetric dihydroxylation reaction
WO2003000021A2 (fr) *	2001-06-22	2003-01-03	Biogen, Inc.	Acides nucleiques et polypeptides pancam

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0821591A1 (fr) *	1995-04-19	1998-02-04	Acorda Therapeutics	Modulateurs de la croissance de l'axone et des dendrites du systeme nerveux central, compositions, cellules et procedes dans lesquels ils sont mis en uvre et utilises

1998
- 1998-02-12 CA CA002243984A patent/CA2243984A1/fr not_active Abandoned
- 1998-02-12 EP EP98903197A patent/EP0910641A1/fr not_active Ceased
- 1998-02-12 WO PCT/GB1998/000434 patent/WO1998036062A1/fr not_active Ceased
- 1998-02-12 JP JP10535471A patent/JPH11507845A/ja active Pending
2002
- 2002-01-09 JP JP2002002285A patent/JP2002300892A/ja active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017000148A (ja) *	2008-10-01	2017-01-05	イマティクスバイオテクノロジーズゲーエムベーハー	神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法

Also Published As

Publication number	Publication date
CA2243984A1 (fr)	1998-08-20
EP0910641A1 (fr)	1999-04-28
WO1998036062A1 (fr)	1998-08-20
JP2002300892A (ja)	2002-10-15

Publication	Publication Date	Title
JP2003527067A (ja)	2003-09-16	Ａｃｒｐ３０（３０ｋｄの脂肪細胞補体関連タンパク質）の相同体ａｃｒｐ３０ｒ１ｌ
US6358707B1 (en)	2002-03-19	Human F11 antigen: a novel cell surface receptor involved in platelet aggregation
US20040241805A1 (en)	2004-12-02	Sialoadhesin family member-2 (SAF-2)
JPH1198988A (ja)	1999-04-13	ヒト７膜貫通受容体をコードするｃＤＮＡクローンＨＥＯＡＤ５４
US6359116B1 (en)	2002-03-19	Compounds
US6245550B1 (en)	2001-06-12	Cytokine family member EF-7
US6187560B1 (en)	2001-02-13	Polynucleotides and polypeptides belonging to the uncoupling proteins family
JP2002300892A (ja)	2002-10-15	神経細胞付着スプライシング変種
JPH11151094A (ja)	1999-06-08	免疫グロブリン遺伝子スーパーファミリーのメンバーｐｉｇｒｌ−１
US20020082385A1 (en)	2002-06-27	Tubby 2 polypeptides
EP0869178A1 (fr)	1998-10-07	SAF-3, un membre de la famille des sialoadhésines
US6657047B2 (en)	2003-12-02	Human Pelota homolog
US20010049121A1 (en)	2001-12-06	Cytokine family member, 2-19
WO1999064629A1 (fr)	1999-12-16	Acrp30r2, un homologe d'acrp30 (proteine apparentee au complement de l'adipocyte 30 kd)
JP2000506397A (ja)	2000-05-30	テイルレス核ホルモン受容体（ｔｌｘ受容体）
US20010009905A1 (en)	2001-07-26	ACRP30R1: A homolog of ACRP30 (30 kd adipocyte complement-related protein)
US6358721B2 (en)	2002-03-19	Human p101 regulatory polypeptide
JP2000026500A (ja)	2000-01-25	Ｌｅｐｒｇｒｐポリペプチドおよびポリヌクレオチド
EP0879886A2 (fr)	1998-11-25	HLDAT86, Protéine de la transduction de signaux et homoloque humaine de Wnt-4
US20020055476A1 (en)	2002-05-09	RAMP2a: receptor activity modifying protein-2a
EP0844253A1 (fr)	1998-05-27	Polynucléotides et polypeptides appartenant à la famille "Tubby"
WO2000061598A2 (fr)	2000-10-19	Profiline-3 du gene specifique du rein de rat
US20010021702A1 (en)	2001-09-13	Guanine nucleotide exchange factor CSB2
JP2001511457A (ja)	2001-08-14	ＥＰＯ一次応答遺伝子であるＥＰＲＧ３ｐｔ
WO2000021993A1 (fr)	2000-04-20	Gene humain ptd010 (tpaaag12)

JPH11507845A - 神経細胞付着分子スプライシング変種 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Related Child Applications (1)

Publications (1)

Family

ID=26147528

Family Applications (2)

Family Applications After (1)

Country Status (4)

Cited By (1)

Families Citing this family (5)

Family Cites Families (1)

Cited By (1)

Also Published As

Similar Documents